Bedridden adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 12,934 adverse event reports that record the MedDRA preferred term Bedridden. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 604 reports in the 12 months to June 2026 and 657 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 879 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 604 (under 0.1%) record this term. Reports for female patients were 63.7% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 150 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Bedridden name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	41
Abilify	Atypical antipsychotic	27
Acetaminophen		39
Aclasta		29
Actemra	Interleukin-6 receptor antagonist	252
Actonel	Bisphosphonate	107
Adalimumab	Tumor necrosis factor blocker	26
Adempas	Soluble guanylate cyclase stimulator	27
Aimovig		33
Ajovy		26
Alemtuzumab	CD52-directed cytolytic antibody	29
Alprazolam	Benzodiazepine	39
Ambrisentan	Endothelin receptor antagonist	89
Ampyra	Potassium channel blocker	130
Apixaban	Factor Xa inhibitor	27
Apo-Leflunomide		33
Arava	Antirheumatic agent	147
Arikayce	Aminoglycoside antibacterial	32
Aripiprazole	Atypical antipsychotic	29
Aspirin	Nonsteroidal anti-inflammatory drug	26
Aubagio	Pyrimidine synthesis inhibitor	58
Avastin	Vascular endothelial growth factor inhibitor	29
Avonex	Interferon beta	71
Baclofen	gamma-Aminobutyric acid-ergic agonist	28
Benlysta	B lymphocyte stimulator-specific inhibitor	41
Butrans	Partial opioid agonist	39
Carbidopa levodopa	Aromatic amino acid	196
Celebrex	Nonsteroidal anti-inflammatory drug	200
Celecoxib	Nonsteroidal anti-inflammatory drug	38
Certolizumab pegol	Tumor necrosis factor blocker	48
Chantix	Partial cholinergic nicotinic agonist	84
Cimzia	Tumor necrosis factor blocker	181
Cipro	Corticosteroid	35
Ciprofloxacin	Fluoroquinolone antibacterial	69
Clonazepam	Benzodiazepine	28
Copaxone		43
Cyclophosphamide	Alkylating drug	30
Cymbalta		57
Depakote	Anti-epileptic agent	30
Dexamethasone	Corticosteroid	32
Diazepam	Benzodiazepine	38
Dilaudid	Opioid agonist	35
Duodopa		149
Duopa	Aromatic amino acid	26
Dupixent	Interleukin-4 receptor alpha antagonist	70
Duragesic		45
Duragesic-100		48
Effexor	Serotonin and norepinephrine reuptake inhibitor	60
Eliquis	Factor Xa inhibitor	67
Enbrel	Tumor necrosis factor blocker	618
Escitalopram	Serotonin reuptake inhibitor	30
Fentanyl	Opioid agonist	65
Fentanyl Transdermal System		33
Forteo	Parathyroid hormone analog	67
Foscarbidopa/foslevodopa		25
Gabapentin	Anti-epileptic agent	89
Hizentra	Human immunoglobulin G	25
Human immunoglobulin g	Human immunoglobulin G	35
Humira		585
Hydrocodone bitartrate and acetaminophen	Opioid agonist	39
Hydroxychloroquine	Antimalarial	48
Hydroxychloroquine sulfate	Antimalarial	51
Ibrance	Kinase inhibitor	32
Ibuprofen	Nonsteroidal anti-inflammatory drug	47
Imbruvica	Kinase inhibitor	33
Infliximab	Tumor necrosis factor blocker	57
Keytruda	Programmed death Receptor-1 blocking antibody	31
Lamictal	Anti-epileptic agent	32
Lamotrigine	Anti-epileptic agent	28
Lantus	Insulin analog	49
Lantus Solostar	Insulin analog	67
Leflunomide	Antirheumatic agent	83
Levaquin		90
Levofloxacin	Fluoroquinolone antibacterial	51
Lipitor	HMG-CoA reductase inhibitor	77
Lupron Depot		41
Lyrica		419
Methotrexate	Folate analog metabolic inhibitor	240
Methotrexate sodium	Folate analog metabolic inhibitor	74
Metoprolol	beta-Adrenergic blocker	28
Mirtazapine		37
Morphine	Opioid agonist	35
Morphine sulfate	Opioid agonist	68
Neurontin		52
Nexavar	Kinase inhibitor	41
Nexium	Proton pump inhibitor	39
Northera		29
Norvasc	Calcium channel blocker	26
Nucala	Interleukin-5 antagonist	29
Nuplazid	Atypical antipsychotic	108
Ocrevus	CD20-directed cytolytic antibody	87
Ofev	Kinase inhibitor	33
Olanzapine	Atypical antipsychotic	28
Omeprazole	Proton pump inhibitor	34
Opsumit	Endothelin receptor antagonist	65
Orencia	Selective T cell costimulation modulator	169
Oxycodone	Opioid agonist	35
Oxycodone and acetaminophen	Opioid agonist	31
Oxycodone hydrochloride	Opioid agonist	108
OxyContin	Opioid agonist	161
Ozempic	GLP-1 receptor agonist	39
Paxil	Serotonin reuptake inhibitor	60
Pegasys	Interferon alpha	33
Plaquenil	Antimalarial	41
Prednisolone	Corticosteroid	120
Prednisolone sodium phosphate	Corticosteroid	28
Prednisone	Corticosteroid	252
Pregabalin		36
Prolia	RANK ligand inhibitor	225
Ramipril	Angiotensin converting enzyme inhibitor	29
Rebif	Interferon beta	115
Reclast	Bisphosphonate	71
Remicade	Tumor necrosis factor blocker	134
Remodulin	Prostacycline vasodilator	25
Repatha	PCSK9 inhibitor	40
Revlimid	Thalidomide analog	62
Ribavirin	Nucleoside analog antiviral	35
Rinvoq	Janus kinase inhibitor	91
Risedronate sodium	Bisphosphonate	81
Risperdal	Atypical antipsychotic	56
Risperidone	Atypical antipsychotic	57
Rituxan	CD20-directed cytolytic antibody	56
Rituximab	CD20-directed cytolytic antibody	70
Rosuvastatin	HMG-CoA reductase inhibitor	27
Rotigotine	Nonergot dopamine agonist	26
Seroquel	Atypical antipsychotic	54
Simponi	Tumor necrosis factor blocker	266
Simvastatin	HMG-CoA reductase inhibitor	26
Skyrizi	Interleukin-23 antagonist	47
Soliris	Complement inhibitor	28
Stelara	Interleukin-12 antagonist	26
Stivarga	Kinase inhibitor	40
Sulfasalazine	Aminosalicylate	116
Sutent	Kinase inhibitor	32
Tecfidera		34
Tegsedi		28
Tracleer	Endothelin receptor antagonist	25
Tramadol		42
Tysabri	Integrin receptor antagonist	42
Uptravi	Prostacyclin receptor agonist	79
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	30
Vivitrol		52
Xanax	Benzodiazepine	28
Xarelto	Factor Xa inhibitor	51
Xeljanz	Janus kinase inhibitor	138
Xgeva	RANK ligand inhibitor	26
Xolair	Anti-IgE	28
Xtandi	Androgen receptor inhibitor	64
Xyrem	Central nervous system depressant	30
Zometa		27

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 51 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Bedridden name, in order of name
Class	Reports with this term
Aminosalicylate	127
Androgen receptor inhibitor	76
Angiotensin 2 receptor blocker	88
Angiotensin converting enzyme inhibitor	56
Anti-epileptic agent	224
Anticholinergic	72
Antimalarial	140
Antirheumatic agent	230
Aromatic amino acid	236
Atypical antipsychotic	499
Benzodiazepine	206
beta-Adrenergic blocker	86
Bisphosphonate	286
CD20-directed cytolytic antibody	215
Corticosteroid	601
Endothelin receptor antagonist	199
Factor Xa inhibitor	156
Fluoroquinolone antibacterial	132
Folate analog metabolic inhibitor	314
GLP-1 receptor agonist	81
HMG-CoA reductase inhibitor	184
Human immunoglobulin G	68
Insulin analog	157
Integrin receptor antagonist	67
Interferon beta	188
Interleukin-23 antagonist	55
Interleukin-4 receptor alpha antagonist	81
Interleukin-5 antagonist	51
Interleukin-6 receptor antagonist	265
Janus kinase inhibitor	245
Kinase inhibitor	299
Nonsteroidal anti-inflammatory drug	368
Opioid agonist	704
Osmotic laxative	55
Parathyroid hormone analog	67
Partial cholinergic nicotinic agonist	94
Partial opioid agonist	61
PCSK9 inhibitor	59
Platinum-based drug	51
Potassium channel blocker	138
Programmed death Receptor-1 blocking antibody	64
Prostacyclin receptor agonist	87
Prostacycline vasodilator	96
Proton pump inhibitor	109
Pyrimidine synthesis inhibitor	76
RANK ligand inhibitor	253
Selective T cell costimulation modulator	210
Serotonin and norepinephrine reuptake inhibitor	164
Serotonin reuptake inhibitor	188
Thalidomide analog	79
Tumor necrosis factor blocker	1,385

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Bedridden, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Bedridden
Age	Reports	Share
Under 2	7	0.1%
2 to 11	27	0.2%
12 to 17	60	0.5%
18 to 44	1,491	11.5%
45 to 64	3,095	23.9%
65 to 74	1,538	11.9%
75 and over	1,820	14.1%
Age not given	4,896	37.9%

Sex of the patient in the reports that record Bedridden
Sex	Reports	Share
Female	8,242	63.7%
Male	3,818	29.5%
Unknown or not given	874	6.8%

Age and sex are as the report gives them. 58% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Bedridden: adverse event reports that record this term. https://reportedreactions.com/reaction/bedridden/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Bedridden mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page